Back to top
more

Alkermes (ALKS)

(Delayed Data from NSDQ)

$26.60 USD

26.60
1,829,055

-0.04 (-0.13%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $26.58 -0.02 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Alkermes Sinks as FDA Refuses Depression Drug Review

by Zacks Equity Research

Alkermes (ALKS) shares declined by more than 21% as it received a Refusal to File letter from the FDA for its pipeline candidate, ALKS 5461, which was developed for major depressive disorder (MDD).

    Zacks Equity Research

    Company News For April 3, 2018

    by Zacks Equity Research

    Companies In The News are: SNX,HUM,TSLA,ALKS

      Zacks Equity Research

      Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates

      by Zacks Equity Research

      Alkermes (ALKS) tops earnings and sales estimates in the fourth quarter of 2017 on the back of strong growth of Vivitrol and Aristada. The company provided a decent outlook for 2018.

        Zacks Equity Research

        Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't?

        by Zacks Equity Research

        Investors need to pay close attention to Alkermes (ALKS) stock based on the movements in the options market lately.

          Zacks Equity Research

          Shire (SHPG) to Report Q4 Earnings: What's in the Cards?

          by Zacks Equity Research

          Shire (SHPG) will report its Q4 results on Feb 14, 2018.

            Zacks Equity Research

            Why Earnings Season Could Be Great for Alkermes (ALKS)

            by Zacks Equity Research

            Alkermes (ALKS) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

              Zacks Equity Research

              Will Ocaliva Sales Dampen Intercept's (ICPT) Q4 Earnings?

              by Zacks Equity Research

              The recent weakness in lead drug Ocaliva sales due to safety issues may mar Intercept's (ICPT) performance in the fourth quarter.

                Zacks Equity Research

                Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?

                by Zacks Equity Research

                Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investors' focus will remain on the company's pipeline on fourth-quarter earnings call.

                  Zacks Equity Research

                  Zoetis (ZTS) Warming Up to Q4 Earnings: What's in Store?

                  by Zacks Equity Research

                  Zoetis (ZTS) is working on returning value to shareholders in the form of share buybacks and dividends.

                    Zacks Equity Research

                    5 Biotech Stocks Set to Trump Estimates This Earnings Season

                    by Zacks Equity Research

                    Total earnings for the medical sector are up 16.9% from the same period last year on 8.5% higher revenues so far.

                      Zacks Equity Research

                      Is a Beat in the Cards for ImmunoGen (IMGN) in Q4 Earnings?

                      by Zacks Equity Research

                      ImmunoGen's (IMGN) significant progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the stock in Q4.

                        Zacks Equity Research

                        Keryx (KERX) Warming Up to Q4 Earnings: What's in Store?

                        by Zacks Equity Research

                        Keryx (KERX) will provide updates on lead drug Auryxia when it reports Q4 results on Feb 7.

                          Zacks Equity Research

                          Is a Beat in Store for Alexion (ALXN) This Earnings Season?

                          by Zacks Equity Research

                          Alexion's (ALXN) Q4 results are likely to driven by Soliris' performance.

                            Zacks Equity Research

                            Strength Seen in Alkermes (ALKS): Stock Soars 8.7%

                            by Zacks Equity Research

                            Alkermes (ALKS) was a big mover last session, as the company saw its shares rise more than 8% on Friday amid huge volumes.

                              Zacks Equity Research

                              Alkermes Submits NDA for Depression Candidate to the FDA

                              by Zacks Equity Research

                              Alkermes (ALKS) files a new drug application to the FDA for ALKS 5461's effective use in the adjunctive treatment of major depressive disorder (MDD).

                                Zacks Equity Research

                                Spectrum Pharmaceuticals Up 134% in 6 Months: Here's Why

                                by Zacks Equity Research

                                Spectrum Pharmaceuticals (SPPI) stock is witnessing significant momentum mainly on encouraging data from poziotinib study.

                                  Zacks Equity Research

                                  BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day

                                  by Zacks Equity Research

                                  BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day

                                    Arpita Dutt headshot

                                    3 Pharma and Biotech Stocks to Watch Out for in 2018

                                    by Arpita Dutt

                                    Here is a look at three pharma and biotech stocks including Alkermes (ALKS) that look well-positioned for 2018.

                                      Zacks Equity Research

                                      Allergan's Vraylar Positive for Bipolar Disease in Phase III

                                      by Zacks Equity Research

                                      Allergan (AGN) releases positive top-line results from a phase III study on Vraylar for treatment of bipolar I depression. The trial meets its primary endpoints with significant progress in patients.

                                        Zacks Equity Research

                                        Surging Earnings Estimates Signal Good News for Alkermes (ALKS)

                                        by Zacks Equity Research

                                        Alkermes (ALKS) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.

                                          Zacks Equity Research

                                          Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)

                                          by Zacks Equity Research

                                          The deal will be beneficial for both companies as it will reduce costs and bring in a strong partner for Alkermes.

                                            Arpita Dutt headshot

                                            Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal

                                            by Arpita Dutt

                                            While there were not too many updates this week, companies like Regeneron (REGN) and Biogen were in the news related to their pipeline.

                                              Zacks Equity Research

                                              Biogen Acquires Worldwide License for Alkermes' MS Candidate

                                              by Zacks Equity Research

                                              Biogen (BIIB) and Alkermes clinch collaboration agreement to develop and commercialize Alkermes' multiple sclerosis candidate, ALKS8700.

                                                Zacks Equity Research

                                                Why Is Alkermes (ALKS) Down 8.3% Since the Last Earnings Report?

                                                by Zacks Equity Research

                                                Alkermes (ALKS) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                  Zacks Equity Research

                                                  Allergan's Vraylar Gets FDA Nod for Maintenance Therapy

                                                  by Zacks Equity Research

                                                  Allergan's (AGN) schizophrenia capsule, Vraylar, secures an FDA approval for its label expansion as a maintenance treatment option in the market.